OPR - Delayed Quote USD

TGTX Apr 2024 19.500 call (TGTX240426C00019500)

0.0800

0.0000

(0.00%)

At close: April 5 at 11:14 AM EDT

Key Events

Loading Chart for TGTX240426C00019500

9/21 12:03 PM

DELL

Previous Close 0.0800
Open 0.0800
Bid 0.0000
Ask 0.8500
Strike 19.50
Expire Date 2024-04-26
Day's Range 0.0800 - 0.0800
Contract Range --
Volume 100
Open Interest 103

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?

Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?

13 Best Biotech Stocks To Buy Under $20

13 Best Biotech Stocks To Buy Under $20

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript

Q4 2023 TG Therapeutics Inc Earnings Call

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

TG Therapeutics Inc (TGTX) Announces Fourth Quarter and Full Year 2023 Financial Results